NCT03042221View on ClinicalTrials.gov

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

November 1, 2026

Study Completion Date

September 30, 2027

Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene MutationALK Gene MutationROSE Cluster 1BRAF V600E
Trial Locations (1)

80045

RECRUITING

University of Colorado, Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER